HGH 191AA

The HGH 191AA evidence base cited here is 6 sources — 1 clinical, 3 review, 1 regulatory. Its strongest evidence is human — a clinical study, most recently 2022 ("Long-term Safety of Growth Hormone in Adults with Growth Hormone Deficie…"). Regulatory status: FDA-approved (various).

• Human growth hormone (somatropin) is a 191-amino-acid pituitary polypeptide. Recombinant HGH is bioidentical to the natural hormone and is FDA-approved — for childhood and adult growth-hormone deficiency, HIV-associated wasting, and several pediatric growth disorders.
• It works both directly (lipolysis, protein synthesis) and indirectly, by stimulating IGF-1 in the liver and tissues — IGF-1 carries much of the growth/anabolic effect.
• The '191AA' label distinguishes true recombinant somatropin from older/inferior 192-aa material; legitimate product is a ~22 kDa, bioidentical protein.

HGH (somatropin/somatotropin) is the body's primary growth hormone, made by the anterior pituitary, and recombinant HGH is the bioidentical pharmaceutical version. Unlike most compounds on this site, it's a long-established FDA-approved drug for defined deficiency states — but it's also widely used off-label for body composition and 'anti-aging', which is where the risk/benefit shifts.

It is prescription-only for its approved uses; off-label use carries legal and health risks. Everything below is research/clinical context, not medical guidance.

Somatropin is a single-chain, 191-amino-acid polypeptide (~22,124 Da) with two intrachain disulfide bridges (4 cysteines). The recombinant form is produced via E. coli DNA technology and is structurally identical to endogenous GH.

The '191AA' designation matters in this market: it signals true 191-residue recombinant somatropin rather than older 192-aa preparations that were more immunogenic and less desirable.

HGH binds growth-hormone receptors and signals through the JAK2-STAT5 pathway. Its direct effects include lipolysis (fat breakdown), protein synthesis, and broad metabolic regulation. Its indirect effects run through IGF-1: HGH stimulates the liver and peripheral tissues to produce IGF-1, which mediates much of the growth, cell-proliferation, and anabolic activity. Subcutaneously it has a ~3-hour half-life and peaks 3–5 hours post-injection.

• Pediatric GH deficiency (idiopathic or organic), plus Turner, Prader-Willi, SGA, Noonan, SHOX deficiency, and chronic renal insufficiency
• Adult GH deficiency (childhood- or adult-onset, e.g. from pituitary tumor/surgery/radiation/trauma) — requires biochemical confirmation
• HIV-associated wasting / cachexia

Approved medical dosing is far lower than the off-label 'performance' ranges. Figures below are context, not guidance — note the steep risk increase at higher doses.

• Medical GHD: ~0.15–0.3 mg/day starting (≈0.5–1 IU), titrated to ~0.4–0.8 mg/day
• Off-label anti-aging/wellness: ~1–2 IU/day
• Off-label body recomposition: ~2–4 IU/day; 'performance' (higher risk): ~4–8 IU/day, usually split AM/PM
• Morning fasted dosing is said to favor fat-burning; evening dosing mimics the natural nocturnal pulse. Doses above ~4 IU are split to reduce side effects.

• Reconstitute with bacteriostatic water added drop-by-drop down the vial wall (e.g. ~1 mL per 10 IU = 0.1 mL/IU); swirl gently, never shake; solution should be clear.
• Refrigerate at 2–8°C and use within ~14–28 days; discard if cloudy, discolored, or if the powder looks melted/stuck (degraded).
• Pharmaceutical brands (Genotropin, Norditropin, Humatrope) or research-grade with a COA; counterfeits are common in this market.

Approved only for specific conditions; off-label use carries legal and health risk. Start low and titrate. HGH causes insulin resistance and can unmask or worsen diabetes (monitor glucose); it can unmask hypothyroidism (monitor thyroid). It is contraindicated with active cancer (may accelerate tumor growth) and in acute critical illness (increased ICU mortality in trials), and should not be used for growth in children with closed epiphyses. Carpal tunnel symptoms are common and dose-related; chronic high-dose use produces acromegaly-like changes (enlarged features, organ growth). Not recommended in pregnancy/breastfeeding.

• KIMS long-term safety (2022, observational, 15,809 adult-GHD patients, mean 5.3 yr): de novo cancer incidence comparable to the general population (SIR 0.92).
• Effects on morbidity (2014 systematic review of RCTs): positive effects on cardiovascular surrogate markers and bone metabolism.
• Adult GHD syndrome (2011): characterized the adult-deficiency syndrome — reduced exercise tolerance, low mood, central adiposity, hyperlipidemia, reduced bone density.

Somatropin is an FDA-approved prescription drug for its defined indications; non-medical use is illegal in the US and prohibited in sport (WADA). Research-grade/underground material is unregulated and frequently counterfeit.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.